Thanks Ankit.
As per this news article, pegs the generic market for Celebrex at $400 million.
"Lupin currently holds 14 per cent market share for Celebrex and expect $58 million sales from the drug with a 15 per cent market share"
However, off late, there are reports of adverse effects from generic Celebrex, read here. So it is debatable how easy it will be for Alembic to garner market share.
Hi Anil,
IMHO the link below can provide us insight that supply is not a concern yet as stock exists after taking into account local supply and exports.
http://www.supima.com/view-reports/supply-and-use/
The winds are favouring the Indian Textile industry and also factories in China are lowering their production due to high overhead costs and hence demand for raw material would decrease in China. The excess raw material can then make way to India.
I was zapped for a moment and then I realized what I had done.
Oh my bad - if you notice carefully, the first section and last section contain inputs that I had solicited from industry experts. For each of the companies I track, I keep a master document containing everything I can lay my hands on the company. In ambika's case, I had copied your blog's inputs verbatim into the word document which was succeeded by inputs from a reputed textile entrepreneur in coimbatore.
I just copied the entire document into VP thread without bothering to remove your blog in the middle. I had no intention of claiming credit or passing off your work as my own.
apologies and sorry about that. Uploading the word doc I maintain on ambika as is - which incidentally has another positive ref check I had done.
ambika.docx (81.0 KB)
As per this http://www.piindustries.com/sites/default/files/As%20Demand%20for%20Faster_1.pdf PI works with Syngenta.
You can also find other names in there.
For its domestic input business, the company licenses and registers products it
considers to have major potential in India from Japanese players such as Kumiai, Mitsui and Nichino, and markets them on an exclusive basis. Additionally, PI works with multinationals that already have a presence in India, such as Bayer CropScience, Syngenta and BASF, and co-markets their products under the PI brand.
MOTILAL OSWAL the Morgan Stanley of India has initiated coverage and said its a 100x stock in its report, after Auctus integration and JV with foreigners and moving into high RoE businesses, they will become big and there will be value migration, buy and buy
I don't know if PI discloses client dealings. In general, absence of merger is actually a good thing for PI since both companies will pursue R&D efforts separately.
Thanks Sam for your effort! looks promising
Disc: invested and added in the current dip
Aurobindo Pharma receives USFDA Approval for Entecavir Tablets
Entecavir tablets are used to treat hepatitis B infection.
Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Entecavir Tablets, 0.5mg and 1mg.
IMS data suggest, entecavir has an estimated market size of $294 million for the 12 months ending June 2015.
The company has now a total of 209 ANDA approvals from the US FDA.
entecavir approval.pdf (74.9 KB)
Hi Rohit - Agree that this will still be capex. But the point i am making is that it is not maintenance capex. On another note, this capex was not mandatory. An option available to Ambika mills was to go for a dedicated feeder and enter into a PPA with another wind power generator and simply buy wind power. Thus capex was not necessary.
This capex allowed them to improve their operating margins in long term and need to be viewed accordingly. Historical rate of increase in electricity tariff in India is 5.5% (CEA data). Few years down the line the wind mills will help in significant power reduction costs.
On a side note - As per an analysis that I have done on some listed companies in textile space, OPM for textile companies that have their captive wind projects is much higher for textile companies that do not have a captive renewable energy source. Companies on left have captive wind mills whereas companies in right do not (except RSWM which has commissioned a 20 MW wind mill an year ago. However even this 20 MW is equivalent to 4 MW of thermal power project. their existing thermal power project is of 50 MW. I am assuming therefore the impact is not much in this case even after having a windmill
